Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$7.41 -0.1%	$8.19	$6.10 ▼ $28.67	$512.80M	1.46	390,492 shs	193,794 shs
CGEN Compugen	$1.65 -0.1%	$1.49	$1.13 ▼ $2.66	$147.07M	2.54	370,824 shs	96,365 shs
MNMD Mind Medicine (MindMed)	$7.06 -0.5%	$6.74	$4.70 ▼ $10.44	$533.01M	2.52	1.36 million shs	932,039 shs
TSHA Taysha Gene Therapies	$2.46 -4.3%	$2.29	$1.05 ▼ $3.31	$528.06M	1.04	3.07 million shs	5.22 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-14.73%	-12.93%	-18.39%	-64.29%
CGEN Compugen	0.00%	-0.60%	+17.02%	+5.10%	-11.29%
MNMD Mind Medicine (MindMed)	0.00%	-2.88%	-6.71%	+5.51%	-3.14%
TSHA Taysha Gene Therapies	0.00%	-3.02%	-12.29%	+56.71%	-13.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.3972 of 5 stars	4.4	1.0	2.1	4.2	0.6
CGEN Compugen	1.4537 of 5 stars	3.5	3.0	1.1	0.0	0.0
MNMD Mind Medicine (MindMed)	1.4135 of 5 stars	3.6	0.0	1.4	0.8	0.6
TSHA Taysha Gene Therapies	3.1855 of 5 stars	4.5	1.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	237.61% Upside
CGEN Compugen	3.00	Buy	$4.00	142.72% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	261.45% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$7.57	207.78% Upside

Current Analyst Ratings Breakdown

Latest CGEN, TSHA, BCYC, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	14.54	N/A	N/A	$11.48 per share	0.65
CGEN Compugen	$27.86M	5.28	N/A	N/A	$0.62 per share	2.66
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	63.39	N/A	N/A	$0.35 per share	7.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
CGEN Compugen	-$14.23M	-$0.16	N/A	N/A	N/A	-51.27%	-24.51%	-12.19%	8/5/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest CGEN, TSHA, BCYC, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
CGEN Compugen	N/A	5.09	5.09
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CGEN Compugen	12.22%
MNMD Mind Medicine (MindMed)	27.91%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
CGEN Compugen	9.50%
MNMD Mind Medicine (MindMed)	2.45%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

CGEN, TSHA, BCYC, and MNMD Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20 at 12:55 PM | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19 at 4:43 AM | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC

June 12, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 5, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.com

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLC

June 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, TSHA, BCYC, and MNMD Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$7.40 -0.01 (-0.07%)

Closing price 03:59 PM Eastern

Extended Trading

$7.24 -0.16 (-2.16%)

As of 04:11 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Compugen NASDAQ:CGEN

$1.65 0.00 (-0.12%)

Closing price 03:59 PM Eastern

Extended Trading

$1.64 0.00 (-0.18%)

As of 04:05 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Mind Medicine (MindMed) NASDAQ:MNMD

$7.06 -0.04 (-0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$7.02 -0.04 (-0.57%)

As of 04:14 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Taysha Gene Therapies NASDAQ:TSHA

$2.46 -0.11 (-4.28%)

Closing price 03:59 PM Eastern

Extended Trading

$2.46 0.00 (-0.20%)

As of 04:12 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time